These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 23607800)
1. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Zhou Q; Gil-Krzewska A; Peruzzi G; Borrego F Clin Exp Immunol; 2013 Jul; 173(1):131-9. PubMed ID: 23607800 [TBL] [Abstract][Full Text] [Related]
2. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863 [TBL] [Abstract][Full Text] [Related]
3. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Wang SY; Racila E; Taylor RP; Weiner GJ Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795 [TBL] [Abstract][Full Text] [Related]
4. Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells. Peruzzi G; Femnou L; Gil-Krzewska A; Borrego F; Weck J; Krzewski K; Coligan JE J Immunol; 2013 Aug; 191(4):1883-94. PubMed ID: 23851692 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity. Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188 [TBL] [Abstract][Full Text] [Related]
6. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Veeramani S; Wang SY; Dahle C; Blackwell S; Jacobus L; Knutson T; Button A; Link BK; Weiner GJ Blood; 2011 Sep; 118(12):3347-9. PubMed ID: 21768303 [TBL] [Abstract][Full Text] [Related]
7. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. Terszowski G; Klein C; Stern M J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454 [TBL] [Abstract][Full Text] [Related]
8. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Kern DJ; James BR; Blackwell S; Gassner C; Klein C; Weiner GJ Leuk Lymphoma; 2013 Nov; 54(11):2500-5. PubMed ID: 23452151 [TBL] [Abstract][Full Text] [Related]
9. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103 [TBL] [Abstract][Full Text] [Related]
10. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. Tang CC; Isitman G; Bruneau J; Tremblay C; Bernard NF; Kent SJ; Parsons MS Clin Exp Immunol; 2015 Aug; 181(2):275-85. PubMed ID: 25644502 [TBL] [Abstract][Full Text] [Related]
11. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094 [TBL] [Abstract][Full Text] [Related]
12. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280 [TBL] [Abstract][Full Text] [Related]
13. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600 [TBL] [Abstract][Full Text] [Related]
14. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782 [TBL] [Abstract][Full Text] [Related]
15. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab. Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255 [TBL] [Abstract][Full Text] [Related]
16. TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer. Wong JKM; McCulloch TR; Alim L; Omer N; Mehdi AM; Tuong ZK; Bonfim-Melo A; Chung E; Nicol A; Simpson F; Rhee H; Rossi GR; Souza-Fonseca-Guimaraes F EBioMedicine; 2024 Jun; 104():105176. PubMed ID: 38810560 [TBL] [Abstract][Full Text] [Related]
17. Compromised NK cell-mediated antibody-dependent cellular cytotoxicity in chronic SIV/SHIV infection. He X; Li D; Luo Z; Liang H; Peng H; Zhao Y; Wang N; Liu D; Qin C; Wei Q; Yan H; Shao Y PLoS One; 2013; 8(2):e56309. PubMed ID: 23424655 [TBL] [Abstract][Full Text] [Related]
18. At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. Danielou-Lazareth A; Henry G; Geromin D; Khaznadar Z; Briere J; Tamouza R; Cayuela JM; Thieblemont C; Toubert A; Dulphy N Eur J Immunol; 2013 May; 43(5):1383-8. PubMed ID: 23400905 [TBL] [Abstract][Full Text] [Related]
19. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Cooley S; Burns LJ; Repka T; Miller JS Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495 [TBL] [Abstract][Full Text] [Related]
20. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. Fujii R; Schlom J; Hodge JW J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]